These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37237839)
1. Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms. Sajib MI; Monteforte M; Go R Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237839 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795 [TBL] [Abstract][Full Text] [Related]
4. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections. Drwiega EN; Griffith NC; Danziger LH Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628 [TBL] [Abstract][Full Text] [Related]
6. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196 [TBL] [Abstract][Full Text] [Related]
7. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections. Gavaghan V; Miller JL; Dela-Pena J Infection; 2023 Apr; 51(2):475-482. PubMed ID: 36201152 [TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms. Wu JY; Srinivas P; Pogue JM Infect Dis Ther; 2020 Mar; 9(1):17-40. PubMed ID: 32072491 [TBL] [Abstract][Full Text] [Related]
9. Compassionate use of cefiderocol for carbapenem-resistant Mabayoje DA; NicFhogartaigh C; Cherian BP; Tan MGM; Wareham DW JAC Antimicrob Resist; 2021 Jun; 3(Suppl 1):i21-i24. PubMed ID: 34223152 [TBL] [Abstract][Full Text] [Related]
10. Cefiderocol-containing regimens for the treatment of carbapenem-resistant Rando E; Cutuli SL; Sangiorgi F; Tanzarella ES; Giovannenze F; De Angelis G; Murri R; Antonelli M; Fantoni M; De Pascale G JAC Antimicrob Resist; 2023 Aug; 5(4):dlad085. PubMed ID: 37484029 [TBL] [Abstract][Full Text] [Related]
12. An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms. Domingues S; Lima T; Saavedra MJ; Da Silva GJ Life (Basel); 2023 Jun; 13(7):. PubMed ID: 37511802 [TBL] [Abstract][Full Text] [Related]
13. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE). Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487 [TBL] [Abstract][Full Text] [Related]
14. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. Falcone M; Tiseo G; Leonildi A; Della Sala L; Vecchione A; Barnini S; Farcomeni A; Menichetti F Antimicrob Agents Chemother; 2022 May; 66(5):e0214221. PubMed ID: 35311522 [TBL] [Abstract][Full Text] [Related]
15. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Lee YR; Yeo S Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics. Matsumoto S; Singley CM; Hoover J; Nakamura R; Echols R; Rittenhouse S; Tsuji M; Yamano Y Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630178 [TBL] [Abstract][Full Text] [Related]
18. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004 [TBL] [Abstract][Full Text] [Related]